Company

Nuformix has developed a risk-mitigated development pipeline targeting high-value unmet needs

Established in Cambridge in 2008, Nuformix has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities with an accompanying portfolio of intellectual property.